2375 – Analysis of Risk Factors for Hepatic Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Bernd Gruhn
Presentation Date: December 6, 2020
Abstract Number: 2375

2845 – Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: James K. McCloskey
Presentation Date: December 7, 2020
Abstract Number: 2845

2386 – Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Mohamad Mohty
Presentation Date: December 6, 2020
Abstract Number: 2386

635 – Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Jeffrey E. Lancet
Presentation Date: December 7, 2020
Abstract Number: 635

3346 – Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Geoffrey L Uy
Presentation Date: December 7, 2020
Abstract Number: 3346

3781 – Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351

Publication Only Abstract
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Author(s): Meagan A. Jacoby et al.
Publication Date: November 5, 2020
Citation: Blood (2020) 136 (Supplement 1): 19.

2572 – Patient Experiences with Liposomal Daunorubicin and Cytarabine (CPX-351) Versus Conventional Induction Regimens: An Analysis of Patient-Reported Outcomes Data from a Prospective Trial

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Thomas W. Leblanc
Presentation Date: December 6, 2020
Abstract Number: 2572

Disclaimer

This content was selected by and is provided to you courtesy of Jazz Pharmaceuticals.

ASH Disclaimer

© 2020 American Society of Hematology. All rights reserved. ASH® and the ASH logo are registered trademarks of the American Society of Hematology. Used with permission.

This content is provided for informational purposes and personal use only, and is not intended to provide medical advice, diagnosis, or treatment or for commercial use. The ideas and opinions expressed herein do not necessarily reflect those of the American Society of Hematology (ASH). The mention of any product, service or therapy in this collection of materials should not be construed as an endorsement of the products mentioned.